Choose a folder
Global DISCOVER data recognized in journal of Cardiovascular Diabetology
Prevalence of vascular complications in patients with type 2 diabetes: a prospective analysis of 15 992 patients.
The DISCOVER study team is pleased to announce that an article describing the prevalence of vascular complications at baseline in the DISCOVER study programme has been published in Cardiovascular Diabetology. The article describes the prevalence of microvascular and macrovascular complications in 15 992 patients with type 2 diabetes initiating a second-line glucose-lowering therapy; the study was conducted in 38 countries across six continents. Factors associated with the prevalence of complications were also assessed.
Overall, the most common microvascular complications were peripheral neuropathy (7.7%), chronic kidney disease (5.0%) and albuminuria (4.3%). Common macrovascular complications included coronary artery disease (8.2%), heart failure (3.3%) and stroke (2.2%). When standardized for age and sex, the prevalence of complications varied substantially between countries and across regions (Figure 1). The age- and sex-standardized prevalence of microvascular complications was 17.9%, and ranged from 14.2% in the Americas to 20.4% in Europe. The age- and sex-standardized prevalence of macrovascular complications was 9.2%, with the lowest prevalence in South-East Asia (4.1%) and the highest prevalence in Europe (18.8%). Results of a multivariable analysis revealed that the factors that were positively associated with the prevalence of both microvascular and macrovascular complications included age, male sex, duration of diabetes and history of hypoglycaemia. HbA1c levels were positively associated with the prevalence of microvascular complications.
These findings revealed that the global burden of vascular complications is high in patients with type 2 diabetes who are relatively early in the disease process, as the median duration of type 2 diabetes was 4.1 years among patients in the study cohort. Given the substantial morbidity and mortality associated with vascular complications, risk factor modification strategies should be a high priority for these patients.
Figure 1. Age- and sex-standardized prevalence of (a) microvascular and (b) macrovascular complications.